Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters
- 1 September 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (9), 3081-3091
- https://doi.org/10.1158/1535-7163.mct-08-0539
Abstract
Molecular and pharmacologic profiling of the NCI-60 cell panel offers the possibility of identifying pathways involved in drug resistance or sensitivity. Of these, decreased uptake of anticancer drugs mediated by efflux transporters represents one of the best studied mechanisms. Previous studies have also shown that uptake transporters can influence cytotoxicity by altering the cellular uptake of anticancer drugs. Using quantitative real-time PCR, we measured the mRNA expression of two solute carrier (SLC) families, the organic cation/zwitterion transporters (SLC22 family) and the organic anion transporters (SLCO family), totaling 23 genes in normal tissues and the NCI-60 cell panel. By correlating the mRNA expression pattern of the SLCO and SLC22 family member gene products with the growth-inhibitory profiles of 1,429 anticancer drugs and drug candidate compounds tested on the NCI-60 cell lines, we identified SLC proteins that are likely to play a dominant role in drug sensitivity. To substantiate some of the SLC-drug pairs for which the SLC member was predicted to be sensitizing, follow-up experiments were performed using engineered and characterized cell lines overexpressing SLC22A4 (OCTN1). As predicted by the statistical correlations, expression of SLC22A4 resulted in increased cellular uptake and heightened sensitivity to mitoxantrone and doxorubicin. Our results indicate that the gene expression database can be used to identify SLCO and SLC22 family members that confer sensitivity to cancer cells. [Mol Cancer Ther 2008;7(9):3081–91]Keywords
Other Versions
This publication has 41 references indexed in Scilit:
- Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporterMolecular Cancer Therapeutics, 2007
- Organic Cation Transporters Are Determinants of Oxaliplatin CytotoxicityCancer Research, 2006
- Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)The Journal of pharmacology and experimental therapeutics, 2006
- Selective Toxicity of NSC73306 in MDR1-Positive Cells as a New Strategy to Circumvent Multidrug Resistance in CancerCancer Research, 2006
- Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panelMolecular Cancer Therapeutics, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Characterization of the organic cation transporter SLC22A16: A doxorubicin importerBiochemical and Biophysical Research Communications, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000